VUF11207 fumarate

Name: VUF11207 fumarate
Brand: MedChemExpress
SKU: HY-110318
Rating: 5.0 (2 reviews)

Cat. No.: HY-110318 Purity: 98.28%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation.

For research use only. We do not sell to patients.

VUF11207 fumarate Chemical Structure

CAS No. : 1785665-61-3

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 129	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 129	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 47	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 100	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 170	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 600	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 1000	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of VUF11207 fumarate:

VUF11207 Get quote

2 Publications Citing Use of MCE VUF11207 fumarate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CXCR Isoform Specific Products:

View All Isoforms

CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

CXCR7

8.1 (pKi)

In Vitro

VUF11207 fumarate (0.17 nM; 5 days) inhibits RANKL‑ and TNF‑α‑induced osteoclastogenesis through CXCL12 inhibition in osteoclast precursor cells^[1].
VUF11207 fumarate inhibits osteoclastogenesis by suppressing phosphorylation of erk^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Osteoclast precursor cells (RANKL‑ and TnF‑α‑induced)
Concentration:	0.17 nM (100 ng/mL)
Incubation Time:	5 days
Result:	Showed inhibitory effect on CXCL12.

In Vivo

VUF11207 fumarate (100 µg/day; s.c.; single daily for 5 days) inhibits LPS‑induced osteoclastogenesis, bone resorption and production of RANKL and TNF‑α in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male c57Bl/6J wild‑type/WT mice (8‑10‑week‑old; 20‑25 g; LPS-induced)^[1]
Dosage:	100 µg/day
Administration:	Subcutaneous injection; single daily for 5 days
Result:	Significantly decreased the number of osteoclasts and suppressed Cathepsin K mRNA, ranKl and TnF‑α mRNA expression levels. Reduced the area of LPS-induced bone resorption.

Molecular Weight

586.65

Formula

C₃₁H₃₉FN₂O₈

CAS No.

1785665-61-3

Appearance

Solid

Color

Light yellow to yellow

SMILES

C/C(CN(C(C1=CC(OC)=C(C(OC)=C1)OC)=O)CCC2N(CCC2)C)=C\C3=C(C=CC=C3)F.OC(/C=C/C(O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (170.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7046 mL	8.5230 mL	17.0459 mL
5 mM	0.3409 mL	1.7046 mL	3.4092 mL
10 mM	0.1705 mL	0.8523 mL	1.7046 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.50%

Select Batch:

Data Sheet (284 KB) SDS (252 KB)

COA (258 KB) HNMR (217 KB) LCMS (141 KB)

Handling Instructions (2659 KB)

References

[1]. Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92. [Content Brief]

[2]. Nugraha AP, et al. C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep. 2022 Mar;25(3):78. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7046 mL	8.5230 mL	17.0459 mL	42.6148 mL
	5 mM	0.3409 mL	1.7046 mL	3.4092 mL	8.5230 mL
	10 mM	0.1705 mL	0.8523 mL	1.7046 mL	4.2615 mL
	15 mM	0.1136 mL	0.5682 mL	1.1364 mL	2.8410 mL
	20 mM	0.0852 mL	0.4261 mL	0.8523 mL	2.1307 mL
	25 mM	0.0682 mL	0.3409 mL	0.6818 mL	1.7046 mL
	30 mM	0.0568 mL	0.2841 mL	0.5682 mL	1.4205 mL
	40 mM	0.0426 mL	0.2131 mL	0.4261 mL	1.0654 mL
	50 mM	0.0341 mL	0.1705 mL	0.3409 mL	0.8523 mL
	60 mM	0.0284 mL	0.1420 mL	0.2841 mL	0.7102 mL
	80 mM	0.0213 mL	0.1065 mL	0.2131 mL	0.5327 mL
	100 mM	0.0170 mL	0.0852 mL	0.1705 mL	0.4261 mL